Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 620.00 GBp
Change Today +14.00 / 2.31%
Volume 419.4K
GWP On Other Exchanges
Symbol
Exchange
London
NASDAQ GM
Frankfurt
NASDAQ GM
Stuttgart
As of 11:35 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

gw pharmaceuticals plc (GWP) Snapshot

Open
599.00 GBp
Previous Close
606.00 GBp
Day High
620.00 GBp
Day Low
593.50 GBp
52 Week High
04/15/15 - 622.50 GBp
52 Week Low
04/22/14 - 225.00 GBp
Market Cap
1.5B
Average Volume 10 Days
437.9K
EPS TTM
-0.07 GBp
Shares Outstanding
237.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GW PHARMACEUTICALS PLC (GWP)

gw pharmaceuticals plc (GWP) Details

GW Pharmaceuticals plc, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. It operates in three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of multiple sclerosis symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.

294 Employees
Last Reported Date: 02/4/15
Founded in 1998

gw pharmaceuticals plc (GWP) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: 567.8K GBP
Founder, Executive Chairman and Chairman of N...
Total Annual Compensation: 696.1K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 389.8K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 421.8K GBP
Research & Development Director and Executive...
Total Annual Compensation: 475.3K GBP
Compensation as of Fiscal Year 2014.

gw pharmaceuticals plc (GWP) Key Developments

GW Pharmaceuticals plc Starts Phase 3 Trial for Epidiolex in Dravet Syndrome

GW Pharmaceuticals plc announced it has initiated the Phase 3 part of a Phase 2/3 clinical trial of Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW anticipates that top-line data from this trial will be available around the end of 2015. The Phase 3 trial is the second part of a two-part randomized double-blind, placebo-controlled parallel group safety, tolerability, pharmacokinetic and efficacy trial of Epidiolex to treat Dravet syndrome in children who are being treated with other anti-epileptic drugs. Part one completed in February 2015 and comprised the pharmacokinetic and dose-finding elements of the trial in a total of 34 patients over a three week treatment period. The dose for part two has been determined as 20mg/kg by a Data Safety Monitoring Committee (DSMC) after assessment of the part one safety and pharmacokinetic data. Part two is a 14-week comparison of Epidiolex versus placebo in a total of 100 patients to assess the safety and efficacy as an adjunctive antiepileptic treatment. The primary measure of this trial will be the percentage change from baseline in convulsive seizure frequency during the maintenance period of the study in patients taking Epidiolex versus placebo. Several additional efficacy and safety secondary outcome measures will be analysed. Part two will recruit an entirely new group of patients who did not participate in part one. Following their participation in the study, all patients are eligible to receive Epidiolex under a long term open label extension study. GW anticipates commencing the second pivotal Phase 3 trial in Dravet syndrome soon after this first trial, which will run in parallel with this Phase 2/3 trial. The Company also expects to commence two Phase 3 clinical trials in Lennox-Gastaut syndrome early in the second quarter of 2015. These additional pivotal trials are all expected to complete recruitment in 2015.

GW Pharmaceuticals plc Presents at Merrill Lynch Smid Cap Conference 2015, Mar-18-2015 08:00 AM

GW Pharmaceuticals plc Presents at Merrill Lynch Smid Cap Conference 2015, Mar-18-2015 08:00 AM. Venue: Four Seasons Hotel, 200 Boylston street, Boston, Massachusetts, United States. Speakers: Justin D. Gover, Chief Executive Officer, Managing Director and Executive Director.

GW Pharmaceuticals plc Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

GW Pharmaceuticals plc Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GWP:LN 620.00 GBp +14.00

GWP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cannabis Science Inc $0.04 USD +0.0018
Medical Marijuana Inc $0.09 USD +0.001
PharmaCyte Biotech Inc $0.20 USD -0.0135
View Industry Companies
 

Industry Analysis

GWP

Industry Average

Valuation GWP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 46.2x
Price/Book 9.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 46.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GW PHARMACEUTICALS PLC, please visit www.gwpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.